



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Nanayakkara, N;Pease, A;Ranasinha, S;Wischer, N;Andrikopoulos, S;Speight, J;De Courten, B;Zoungas, S

Title:

Depression and diabetes distress in adults with type 2 diabetes: Results from the Australian National Diabetes Audit (ANDA) 2016

Date:

2018-12-01

Citation:

Nanayakkara, N., Pease, A., Ranasinha, S., Wischer, N., Andrikopoulos, S., Speight, J., De Courten, B. & Zoungas, S. (2018). Depression and diabetes distress in adults with type 2 diabetes: Results from the Australian National Diabetes Audit (ANDA) 2016. *Scientific Reports*, 8 (1), <https://doi.org/10.1038/s41598-018-26138-5>.

Persistent Link:

<https://hdl.handle.net/11343/255168>

License:

CC BY

# SCIENTIFIC REPORTS



OPEN

## Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016

Natalie Nanayakkara<sup>1,2</sup>, Anthony Pease<sup>1,2</sup>, Sanjeeva Ranasinha<sup>1</sup>, Natalie Wischer<sup>3</sup>, Sofianos Andrikopoulos<sup>1,4</sup>, Jane Speight<sup>5,6,7</sup>, Barbora de Courten<sup>1,2</sup> & Sophia Zoungas<sup>1,2,8</sup>

This study explores the prevalence of, and factors associated with, likely depression and diabetes distress in adults with type 2 diabetes in a large, national sample. Australian National Diabetes Audit data were analysed from adults with type 2 diabetes attending 50 diabetes centres. The Brief Case find for Depression and Diabetes Distress Score 17 were administered to screen for likely depression and diabetes-related distress, respectively. A total of 2,552 adults with type 2 diabetes participated: (mean  $\pm$  SD) age was  $63 \pm 13$  years, diabetes duration was  $12 \pm 10$  years, and HbA1c was  $8 \pm 2\%$ . Twenty-nine percent of patients had likely depression, 7% had high diabetes distress, and 5% had both. Difficulty following dietary recommendations, smoking, forgetting medications, and diabetes distress were all associated with greater odds of depression whereas higher own health rating was associated with lower odds (all  $p < 0.02$ ). Female gender, increasing HbA1c, insulin use, difficulty following dietary recommendations and depression were all associated with greater odds of diabetes distress & older age, higher own health rating and monitoring blood glucose levels as recommended were associated with lower odds (all  $p < 0.04$ ). Depression was associated with sub-optimal self-care, while diabetes distress was associated with higher HbA1c and sub-optimal self-care.

Driven by ageing, obesity and sedentary lifestyles, type 2 diabetes mellitus (T2DM) currently affects just under 400 million individuals worldwide and is expected to rise exponentially, affecting 592 million by 2035<sup>1</sup>. Globally, depression and diabetes represent the 4<sup>th</sup> and 8<sup>th</sup> cause of disability adjusted life years respectively<sup>2</sup>. Depression and distress in T2DM are associated with greater morbidity, mortality and healthcare costs<sup>3</sup>.

Like many other chronic conditions, T2DM is associated with depression. Depression has been reported to affect up to 40% of patients with diabetes<sup>4–6</sup>. Indeed, individuals with diabetes have a 2–4 fold greater risk of depression when compared to individuals without diabetes<sup>7</sup>. Depression is associated with higher glycated haemoglobin (HbA1c)<sup>8</sup>, higher rates of complications<sup>9,10</sup> and mortality<sup>11</sup>. This association may be mediated by sub-optimal self-care<sup>12</sup>, medication adherence<sup>13</sup>, health-related quality of life<sup>14</sup> and common pathophysiological mechanisms via stress and inflammation<sup>7</sup>. Furthermore, even modest levels of depression are associated with less diabetes self-care<sup>15</sup>. Timely diagnosis and treatment of depression may improve quality of life and increase social and workforce participation for patients as well as family, friends and carers<sup>16,17</sup>.

The negative impact of depression on diabetes may be explained by diabetes distress<sup>18,19</sup>. Diabetes distress refers to the emotional distress related to living with and managing diabetes, not attributable to other causes of overall emotional distress or mental health problems<sup>19,20</sup>. Many adults with diabetes and depressive symptoms experience high levels of emotional distress stemming from their concerns and worries about diabetes<sup>21</sup>.

<sup>1</sup>School Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3168, Australia. <sup>2</sup>Diabetes and Vascular Medicine Unit, Monash Health, Clayton, VIC, 3168, Australia. <sup>3</sup>National Association Diabetes Centres, Sydney, NSW, 2000, Australia. <sup>4</sup>The University of Melbourne, Department of Medicine, Heidelberg, VIC, 3168, Australia. <sup>5</sup>Deakin University, School of Psychology, Geelong, Victoria, Australia. <sup>6</sup>The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Melbourne, Australia. <sup>7</sup>AHP Research, Hornchurch, UK. <sup>8</sup>The George Institute for Global Health, Camperdown, NSW, 2050, Australia. Correspondence and requests for materials should be addressed to S.Z. (email: [sophia.zoungas@monash.edu](mailto:sophia.zoungas@monash.edu))

Population-based surveys demonstrate that both depression and diabetes distress are prevalent among adults with type 2 diabetes<sup>22,23</sup>. Despite this, there is limited data exploring factors associated with depression and diabetes distress in Australian people with type 2 diabetes. We hypothesised that significant levels of depression and diabetes distress in adults with T2DM attending diabetes clinics, are related to demographic, self-care, clinical and healthcare factors. Thus, this large-scale, national, cross-sectional clinic-based study examined the prevalence and factors associated with depression and diabetes distress in adults with T2DM attending diabetes centres across Australia.

## Methods

**Participants and procedures.** Data were analysed from the Australian National Diabetes Audit (ANDA) including patients from 50 diabetes centres across Australia. The state and territory location of participating centres is presented in Supplementary Table 1. Validated screening instruments were administered during the consultation by clinicians on the day of the survey.

Only adults with T2DM were eligible to be included in the current study; adults and children with type 1 diabetes, women with gestational diabetes and those with other forms of diabetes were excluded.

De-identified data were collected by participating diabetes centres during a single 4-week survey period (May/June 2016). Patients were under the care of endocrinologists, general specialists, general practitioners and diabetes nurse educators. Health professionals from participating centres interviewed patients, reviewed medical records and pathology results before recording the information in a standardised data collection form.

All missing data, invalid entries and discrepancies were clarified with the relevant diabetes centres. The conduct of ANDA and use of de-identified data for research purposes was approved by the Monash Health Human Research Ethics Committee and all research was performed in accordance with relevant guidelines/regulations.

**Explanatory Variables.** Pre-specified demographic data (gender, date of birth) and clinical variables (diabetes duration [years], smoking, health professional attendance, glycated haemoglobin A1c [(HbA1c) (within 12 months)], physical activity, diet and medication adherence) were obtained for patients with T2DM. Age and diabetes duration at survey were calculated as year of survey (2016) minus year of birth or year of diabetes diagnosis, respectively. Current smoking status was ascertained at the time of surveys as was physical activity, with sufficient activity defined as  $\geq 150$  total minutes per week as per National Physical Activity Guidelines for Australians<sup>24</sup>. Own Health State Rating was determined on a visual analogue scale (0–100) based on patients' subjective assessment of their health on the day of survey. Patients were considered to be receiving treatment for depression if they were either undergoing counselling by either a psychologist or psychiatrist and/or taking antidepressant medications (not prescribed for peripheral neuropathy).

**Outcome variables.** *Depression.* The Brief Case find for Depression (BCD) was administered to screen for likely depression<sup>25</sup>. Depression was considered likely if at least two affirmative answers were indicated, one in each category of the BCD.

*Diabetes Distress.* The Diabetes Distress Score 17 (DDS17) was administered to screen for diabetes-related distress<sup>26</sup>. Patients were first asked two screening questions, if at least one answer was positive, patients were asked to proceed to the DDS17 questionnaire. The DDS17 questionnaire assesses difficulties related to diabetes experienced during the past month, graded on a Likert scale from 1 (not a problem) to 6 (very serious problem). The DDS17 yields a composite score as well as four subscale scores, each exploring a different source of diabetes distress: emotional burden, physician-related distress, regimen-related distress, and interpersonal distress. An overall mean score  $< 2.0$  indicates little to no diabetes distress, from 2.0–2.9 indicates moderate diabetes distress, and  $\geq 3.0$  indicates a high diabetes distress<sup>27</sup>. Diabetes distress was considered as a dichotomous variable, with patients deemed to have high diabetes distress if DDS17 scores were  $\geq 3$ .

**Statistical analysis.** Categorical variables were summarised as percentages and differences between subgroups analysed using  $\chi^2$  test. Continuous variables were reported as means with standard deviations (SD) or as medians with interquartile ranges (IQR) and tested for normality to determine appropriate statistical analysis (parametric or non-parametric). T tests were performed for normally distributed data and Mann-Whitney U tests for non-normally distributed data. Logistic regression was used to examine factors (age, gender, language, duration, HbA1c, physical activity, diet, smoking, insulin use, medication adherence, glucose monitoring, own health rating and health professional attendance) associated with likely depression and high diabetes distress (as per the categories above). The selection of variables to be entered into each model was based on identifying all variables with possible prognostic importance for the outcomes of interest (and/or exhibiting  $p < 0.10$  on univariate analysis). All analyses were adjusted for age and gender. Patients with missing data for a particular variable were not included in analyses pertaining to that variable, but were not excluded from other analyses where relevant data were available. A two-sided significance level of 0.05 was considered statistically significant. All analyses were performed using Stata software version 14.2 (StataCorp, Texas, USA).

**Data Sharing Statement.** Application for datasets generated during and/or analysed during the current study may be considered by the corresponding author on reasonable request.

## Results


Data from 2,552 adults ( $\geq 18$  years of age) with T2DM were analysed. Mean ( $\pm$  SD) age was  $63 \pm 13$  years, T2DM duration was  $12 \pm 10$  years, and HbA1c was  $8.0 \pm 2.0\%$ . Country of birth was reported as Australia by most patients (65%) followed by England (4%) and New Zealand (3%). No depression and little to moderate diabetes distress was reported by 1663 adults (65%), no depression and high diabetes distress by 56 adults (2%),

Characteristic	Likely depression			
	Yes		No	
	Diabetes Distress		Diabetes Distress	
N = 2552	Yes	No	Yes	No
Participants (n)	126	572	51	1668
Age to 2016 (years), mean (SD)	56.4 ± 11.3	60.5 ± 12.6	54.7 ± 13.0	64.1 ± 12.5
Male, n (%)	51 (41)	306 (54)	19 (37)	954 (57)
Non-English speaking <sup>2</sup>	2 (2)	29 (5)	0 (0)	88 (5)
Diabetes duration (years), mean (SD)	12.2 ± 8.3	11.8 ± 9.6	10.8 ± 7.2	11.7 ± 9.7
<b>Lifestyle</b>				
Sufficient Physical Activity <sup>3</sup> , n (%)	19 (15)	176 (31)	15 (29)	705 (42)
Difficulties following the recommended diet, n (%)	91 (72)	280 (49)	36 (71)	525 (31)
Current smoking, n (%)	26 (21)	100 (18)	8 (15.7)	164 (9.8)
<b>Diabetes management</b>				
HbA1c <sup>1</sup> (%), mean (SD)	9.3 ± 2.1	8.4 ± 1.9	9.3 ± 2.0	8.1 ± 1.8
HbA1c <sup>1</sup> (mmol/mol), mean (SD)	78.4 ± 23	68.1 ± 20.7	78.6 ± 20.8	65.2 ± 20.1
Above target HbA1c (7.0%), n (%)	97 (83)	396 (74)	41 (84)	1057 (68)
Insulin, n (%)	96 (76)	362 (63)	38 (74)	915 (55)
Do you forget to take your medications? n (%)	66 (52)	209 (37)	24 (47)	360 (22)
<b>Blood glucose testing</b>				
Tests blood glucose level as often as recommended	58 (46)	159 (28)	19 (37)	407 (25)
Does not check blood glucose level as often as recommended	62 (49)	368 (65)	30 (59)	1,157 (70)
Unsure of recommendation	6 (5)	39 (7)	2 (4)	94 (6)
<b>Health professional attendances<sup>3</sup></b>				
Diabetes specialist review <sup>4</sup>	85 (67)	377 (66)	37 (73)	1,059 (64)
Diabetes educator review <sup>4</sup>	81 (64)	436 (76)	41 (80)	1,201 (72)
Dietitian, n (%)	58 (46)	306 (54)	27 (53)	811 (49)
Podiatrist, n (%)	88 (70)	378 (66)	31 (61)	1,084 (65)
Ophthalmologist and/or Optometrist, n (%)	96 (76)	471 (82)	44 (86)	1,370 (82)
<b>Physical health</b>				
Own health state rating (0–100), mean (SD)	43 ± 20	57 ± 21	57 ± 18	70 ± 18
<b>Psychological health</b>				
Depression <sup>5</sup> , n (%)	126 (100)	572 (100)	0 (0)	0 (0)
Treated for depression, n (%)	60 (48)	228 (40)	17 (33)	282 (17)
Taking antidepressants <sup>6</sup> , n (%)	54 (43)	189 (33)	15 (29)	249 (15)
Undergoing counselling, n (%)	26 (21)	103 (18)	8 (16)	97 (6)
Diabetes Distress overall score <sup>7</sup>	126 (100)	0 (0)	51 (100)	0 (0)
Emotional distress score <sup>6</sup> , n (%)	120 (95)	89 (16)	44 (86)	69 (4)
Physician- related distress score <sup>6</sup> , n (%)	50 (40)	9 (2)	19 (37)	7 (0.4)
Regimen- related distress score <sup>6</sup> , n (%)	110 (87)	78 (14)	44 (86)	57 (3)
Interpersonal distress score <sup>6</sup> , n (%)	83 (66)	37 (6)	27 (53)	29 (2)

**Table 1.** Participant characteristics by depression and diabetes distress status. <sup>1</sup>Within 6 months of survey; <sup>2</sup>defined as requirement of interpreter for appointment; <sup>3</sup>Sufficient physical activity for health benefit is defined as ≥150 total minutes per week; <sup>4</sup>Attended within the last 12 months; <sup>5</sup>As indicated by the Brief Case-Find for Depression (BCD); <sup>6</sup>Not prescribed for peripheral neuropathy; <sup>7</sup>As indicated by Diabetes Distress 17 Score; \*Categorical variables were summarised as percentages.

depression and little to moderate diabetes distress by 578 adults (23%), and depression and high diabetes distress by 120 adults (5%). Participant characteristics are described in Table 1.

**Likely Depression.** Thirty percent of adults with T2DM had a BCD score suggesting likely depression, more than half of whom (17% of total) were not receiving any treatment, while just under half (13% of total) were receiving counselling and/or pharmacotherapy (Fig. 1). Age, female gender, higher HbA1c, insufficient physical activity, difficulty following dietary recommendations, smoking, insulin use, forgetting medications, not monitoring blood glucose levels, treatment for depression, lower own health rating and diabetes distress were significantly associated with depression (univariable  $p < 0.010$ , Table 2). In multivariable analysis adjusting for anti-depressant treatment, difficulty following dietary recommendations, current smoking, forgetting medications, and diabetes distress were associated with greater odds of depression whereas higher own health rating was associated with lower odds of depression (all  $p < 0.002$ , Table 2). Female gender was not associated with increased risk of



**Figure 1.** Adults with type 2 diabetes and likely depression.

depression after adjustment for potential confounding factors such as age, insulin use, HbA1c, smoking status, medication adherence, diet difficulty, physical activity, glucose monitoring, use of antidepressant medications or counselling, own health rating and diabetes distress score [0.96 (0.77–1.18),  $p = 0.672$ ].

**Diabetes Distress.** Seven percent of patients had a DDS 17 score suggesting high diabetes distress. Age, female gender, higher HbA1c, insulin use, smoking, forgetting medications, difficulty following dietary recommendations, insufficient physical activity, not monitoring blood glucose levels, depression, treatment for depression and lower own health rating were significantly associated with diabetes distress (univariable  $p < 0.032$  Table 3). In multivariable analysis, female gender, higher HbA1c, insulin use, difficulty following dietary recommendations, and depression were associated with greater odds of diabetes distress whereas older age, higher own health rating and monitoring blood glucose levels as recommended were associated with lower odds of diabetes distress (all  $p < 0.04$ , Table 3).

Younger age, insulin use, a requirement for an interpreter, difficulty following dietary recommendations, higher HbA1c, depression, treatment for depression, and lower own health rating were associated with greater odds of emotional distress after adjustment for gender, current smoking, forgetting medications, sufficient physical activity, diabetes specialist review, and not monitoring blood glucose levels (Supplementary Table 2). Younger age, female gender, insufficient physical activity, depression and lower own health rating were associated with greater odds of physician-related distress on adjusted analysis (Supplementary Table 2). Younger age, requirement for an interpreter, forgetting medications, difficulty following dietary recommendations, higher HbA1c, depression, treatment for depression, not monitoring blood glucose levels and lower own health rating were associated with greater odds of regimen-related distress on adjusted analysis (Supplementary Table 2). Younger age, female gender, insulin use, difficulty following dietary recommendations, higher HbA1c, depression, treatment for depression and lower own health rating were associated with greater odds of interpersonal distress on adjusted analysis (Supplementary Table 2). Female gender was associated with increased risk of diabetes distress after adjustment for potential confounding factors such as age, insulin use, HbA1c, smoking status, interpreter use, medication adherence, diet difficulty, physical activity, glucose monitoring, likely depression, use of antidepressant medications or counselling and own health rating [1.59 (1.11–2.27),  $p = 0.012$ ]. Factors associated with diabetes distress among women and men with type 2 diabetes slightly differed with a greater number among women (younger age, insulin use, higher HbA1c, requirement for interpreter, diet difficulty, being unsure of glucose monitoring recommendations, likely depression and lower own health rating) than among men (higher HbA1c, diet difficulty, likely depression and lower own health rating) (data not shown).

## Discussion

In this large national study, we found that approximately one third of patients with T2DM attending diabetes centres suffer from likely depression and diabetes distress, and that a substantial proportion remain untreated. Patients with depression or diabetes distress were less likely to achieve the recommendations for smoking cessation, diet, physical activity, and blood glucose monitoring. These effects remained significant after adjustment for other relevant confounders.

**Likely Depression.** It is of concern that a significant proportion of our patients with T2DM are likely to have comorbid depression with the majority untreated. The rate of depression we observed was comparable to that of other studies from Australia<sup>22</sup>, USA<sup>28</sup> and China<sup>29,30</sup>. These findings underscore the importance of guidelines recommending clinicians screen, identify and treat depression at the earliest stages of diabetes<sup>31</sup>.

The brief case find for depression is a screening tool for use in general medical and geriatric patients. It has been validated in populations with chronic illness where it was found to have good sensitivity and agreement with other screening tools for depression such as the Primary Care Evaluation of Mental Disorders (PRIME-MD) and the Hospital Anxiety and Depression Scale (HADS)<sup>32,33</sup>. Although clinical psychiatric interview remains the gold standard for diagnosis of depression, this is not usually feasible in the setting of an outpatient diabetes consultation. The BCD can be administered quickly to those at risk of depression before referral to mental health services. A limitation is that it does not allow for determination of symptom severity or impact on daily living and unlike the HADS screen, it does not screen for other mental health conditions such as anxiety. Indeed, depression screening should ideally be followed by further assessment, diagnosis and treatment, if necessary. We did not assess the impact of case finding via the BCD on the subsequent management of patients, and therefore cannot determine in what proportion of patients this screening led to a formal diagnosis of depression.

Factor	Univariable Analysis		Multivariable Analysis	
	OR (95%CI)	p value	OR (95%CI)	p value
<b>Age</b>				
Per 1 year increase	0.97 (0.97–0.98)	<0.001	0.99 (0.98–1.00)	0.086
<b>Sex</b>				
Male (ref)				
Female	1.27 (1.07–1.50)	0.007	0.96 (0.77–1.18)	0.672
<b>Non-English speaking<sup>2</sup></b>				
Yes (ref)				
No	1.10 (0.74–1.64)	0.638		
<b>Diabetes Duration</b>				
1 year increase	1.00 (0.99–1.01)	0.945		
<b>HbA1c<sup>1</sup>%</b>				
per unit increase	1.11 (1.06–1.16)	<0.001	0.99 (0.94–1.05)	0.849
<b>Sufficient physical activity<sup>3</sup></b>				
No (ref)				
Yes	0.51 (0.42–0.62)	<0.001	0.84 (0.67–1.05)	0.123
<b>Difficulties following dietary recommendations</b>				
No (ref)				
Yes	2.38 (2.00–2.83)	<0.010	1.42 (1.14–1.78)	0.002
<b>Current smoking</b>				
No (ref)				
Yes	1.97 (1.54–2.51)	<0.001	1.46 (1.08–1.97)	0.013
<b>Insulin use</b>				
No (ref)				
Yes	1.53 (1.28–1.82)	<0.001	1.11 (0.88–1.39)	0.376
<b>Forgets medications</b>				
No (ref)				
Yes	2.28 (1.90–2.74)	<0.001	1.47 (1.16–1.85)	0.001
<b>Monitors blood glucose as recommended</b>				
No (ref)				
Yes	0.70 (0.58–0.85)	<0.001	1.00 (0.79–1.27)	0.998
Unsure of recommended testing	0.90 (0.62–1.31)	0.592	1.22 (0.77–1.94)	0.405
<b>Treated for depression<sup>4</sup></b>				
No (ref)				
Yes	3.34 (2.76–4.03)	<0.001	2.22 (1.77–2.79)	<0.001
<b>Own health rating (1–100)</b>				
per 1 point increase	0.96 (0.96–0.97)	<0.001	0.97 (0.97–0.98)	<0.001
<b>Diabetes Distress<sup>5</sup></b>				
No				
Yes	7.20 (5.13–10.11)	<0.001	3.18 (2.16–4.69)	<0.001
<b>Diabetes Specialist<sup>6</sup></b>				
No (ref)				
Yes	1.14 (0.95–1.36)	0.159		
<b>Diabetes Educator<sup>6</sup></b>				
No (ref)				
Yes	1.13 (0.93–1.37)	0.220		

**Table 2.** Factors associated with Likely Depression<sup>#</sup>. <sup>1</sup>Within 6 months of survey. <sup>2</sup>Defined as requirement of interpreter for appointment. <sup>3</sup>Sufficient physical activity for health benefit is defined as  $\geq 150$  total minutes per week. <sup>4</sup>Undergoing counselling or prescribed antidepressant medications. <sup>5</sup>As indicated by Diabetes Distress 17 Score. <sup>6</sup>Attended within the last 12 months. <sup>#</sup>As indicated by the Brief Case-Find for Depression (BCD).

It is possible that the cross-sectional association we report may be bidirectional. Patients with depression may be more prone to diabetes, or alternatively people with diabetes may be more vulnerable to depression. For example, while some prospective studies have found that depressive symptoms are associated with a 60% increased risk of diabetes<sup>34</sup> others report a 24% increased risk of depression in patients with diabetes<sup>35</sup>. Further research is

Factor	Univariable Analysis		Multivariable Analysis	
	OR (95%CI)	p value	OR (95%CI)	p value
<b>Age</b>				
Per 1 year increase	0.96 (0.95–0.97)	<0.001	0.98 (0.96–0.99)	0.006
<b>Sex</b>				
Male (ref)				
Female	1.99 (1.45–2.72)	<0.001	1.59 (1.11–2.27)	0.012
<b>Duration</b>				
1 year increase	1.00 (0.99–1.02)	0.891		
<b>HbA1c<sup>1</sup>%</b>				
per unit increase	1.30 (1.21–1.40)	<0.001	1.18 (1.07–1.29)	<0.001
<b>Insulin use</b>				
No (ref)				
Yes	2.29 (1.62–3.26)	<0.001	1.56 (1.02–2.37)	0.039
<b>Current smoking</b>				
No (ref)				
Yes	1.77 (1.19–2.63)	0.005	0.83 (0.51–1.33)	0.436
<b>Forgets medications</b>				
No (ref)				
Yes	3.00 (2.20–4.09)	<0.001	1.20 (0.82–1.75)	0.339
<b>Difficulties following dietary recommendations</b>				
No (ref)				
Yes	4.54 (3.23–6.36)	<0.001	2.25 (1.52–3.32)	<0.001
<b>Sufficient physical activity<sup>3</sup></b>				
No (ref)				
Yes	0.36 (0.25–0.53)	<0.001	0.72 (0.47–1.12)	0.149
<b>Monitors blood glucose as recommended</b>				
No (ref)				
Yes	0.45 (0.33–0.61)	<0.001	0.67 (0.46–0.98)	0.038
Unsure of recommended testing	0.44 (0.21–0.93)	0.032	0.45 (0.18–1.13)	0.091
<b>Depression<sup>5</sup></b>				
No				
Yes	7.20 (5.13–10.11)	<0.001	3.35 (2.26–4.95)	<0.001
<b>Treated for depression<sup>4</sup></b>				
No (ref)				
Yes	2.58 (1.89–3.53)	<0.001	1.21 (0.84–1.77)	0.308
<b>Own health rating (1–100)</b>				
per 1 point increase	0.96 (0.95–0.96)	<0.001	0.97 (0.96–0.98)	<0.001
<b>Diabetes Specialist<sup>6</sup></b>				
No (ref)				
Yes	1.22 (0.88–1.69)	0.233		
<b>Diabetes Educator<sup>6</sup></b>				
No (ref)				
Yes	0.80 (0.58–1.12)	0.191		

**Table 3.** Factors associated with Diabetes Distress<sup>#</sup>. <sup>1</sup>Within 6 months of survey. <sup>2</sup>Defined as requirement of interpreter for appointment. <sup>3</sup>Sufficient physical activity for health benefit is defined as  $\geq 150$  total minutes per week. <sup>4</sup>Undergoing counselling or prescribed antidepressant medications. <sup>5</sup>As indicated by the Brief Case-Find for Depression (BCD). <sup>6</sup>Attended within the last 12 months. <sup>#</sup>As indicated by Diabetes Distress 17 Score.

required to elucidate the direction and underlying mechanisms linking diabetes<sup>36</sup> and depression. Some studies suggest that diagnosed diabetes is associated with depression but undiagnosed is not<sup>37</sup> whereas other studies report that both diagnosed and undiagnosed diabetes are associated with depression, suggesting physiological rather than psychological mechanisms<sup>38</sup>. The limited data examining the relationship between depression and HbA1c levels show mixed results<sup>39</sup>. One study found elevated HbA1c levels among people with diabetes and depression compared with people with diabetes and no depression<sup>40</sup> whilst other studies found either no

relationship between HbA1c levels and depression<sup>41</sup>. Yet others indicate that HbA1c is correlated with depression among people with short but not long term depression<sup>39</sup>. Some studies have also observed a relationship exists between HbA1c levels and depression among people using insulin but not for those using non-insulin hypoglycaemic agents<sup>42</sup>. Furthermore, studies report that pharmacotherapy for the treatment of depression may lead to poorer diabetes control and adverse metabolic indices<sup>43</sup>, although this may vary with the medication used<sup>44</sup>. Understanding these complex relationships may lead to better management strategies and therefore improved outcomes for patients with co-morbid depression and diabetes.

**Diabetes Distress.** Diabetes distress needs to be differentiated from depression due to differences in the origins and appropriate management<sup>19</sup>. The 17-item Diabetes Distress Scale (DDS17) is a widely used and validated measure for assessing diabetes-specific distress, with high reliability and validity across many settings, countries and cultures<sup>27,45–47</sup>. The DDS17 items can be used to identify areas of specific patient concern, to enable clinicians to initiate discussions that acknowledge and address diabetes-related difficulties, provide reassurance and initiate behavioural change. Studies indicate that this is most successful when the conversation is initiated by clinicians<sup>48</sup>. Timely detection and management of diabetes distress is associated with better self-care, quality of life and health outcomes<sup>20</sup>. The rate of diabetes distress in our study is comparable to that reported in other studies. We also found that most of the distress reported was in the domains of regimen-related distress and emotional burdens: ‘feeling that they will end up with serious long-term complications regardless of what they do’ and that ‘diabetes and/or hypertension are consuming too much of their mental and physical energy’ followed by ‘feeling that they are not closely adhering to a good meal plan’. In studies conducted in Denmark<sup>49</sup>, China<sup>50</sup> and Mexico<sup>46</sup>, regimen-related distress and emotional burden were also a greater source of diabetes distress than interpersonal or physician related distress.

**Depression and Distress.** Depression and diabetes distress can decrease adherence to self-care practices, and in turn, contribute to higher HbA1c levels<sup>51</sup>. Patients with depression are also less likely to discuss self-care practices with health professionals<sup>52</sup>. Here, we report that HbA1c was associated with diabetes distress, but was not associated with depression after adjustment for other potential confounders. This is likely due to depressive symptoms hindering diabetes self-care, even in patients with symptoms insufficient to make the diagnosis of major depression<sup>36</sup>. We found that diabetes distress but not depression was associated with insulin use after adjustment for other potential confounders. Others<sup>53</sup> have similarly reported a positive association between diabetes distress and insulin use rather than depression in Turkey and China<sup>30</sup>, suggesting the relationships are consistent across cultures.

**Strengths and Limitations.** A strength of this analysis is the nation-wide survey with a large dataset of patients. Data were sourced from the majority of centres registered with the National Association of Diabetes centres (NADC). Thus participants of our study are likely to be representative of patients attending diabetes centres. We obtained information on a broad range of variables with potential impact on mental health. Limitations include that the majority of patients received care at tertiary diabetes centres and may differ from a primary care treated patient group. Further, referral bias is also possible as general practitioners may be more likely to refer more challenging patients whilst managing other patients with better control; skewing results towards a more complex patient cohort with more significant mental health concerns. Alternatively, patients with interrelating co-morbid psychological conditions may also be more likely to be referred. Another limitation was the reliance on self/healthcare worker reports as we were unable to independently verify diagnoses and treatments. This is unlikely to change our findings substantively, as previous research has found approximately 90% of self-reported diabetes information to be valid<sup>54</sup>. We were unable to conduct longitudinal analyses to identify the direction of the reported relationships as the data were obtained in a de-identified format. Our study highlights the need for further prospective studies to examine cause and effect. Our study population was predominantly Australian-born and English speaking, our findings may not be generalisable to other populations. However, the requirement for an interpreter was not associated with either depression or diabetes distress. There was insufficient ethnic variation in our study population for analysis by ethnicity. The BCD is a categorical measure and does not indicate the severity of depression; further studies are required to elucidate if the degree of glycaemic control is associated with the severity of depression. We did not obtain data for the patients who refused or were unable to answer the questions informing this analysis, thus we have no clear indication if or how non-response could have altered our results. However, non-response was rather low (5%).

## Conclusion

The findings of this study emphasise the importance of screening for and addressing emotional and psychological health in people with type 2 diabetes, and highlight the need for longitudinal data to elucidate the determinants of depression and diabetes distress in type 2 diabetes. Given the high prevalence of depression and diabetes distress, routine screening of patients with type 2 diabetes should be encouraged to optimise mental health and improve quality of life.

## References

1. Guariguata, L. *et al.* Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes research and clinical practice* **103**, 137–149 (2014).
2. DALYs, G. B. D. & Collaborators, H. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* **388**, 1603–1658, [https://doi.org/10.1016/S0140-6736\(16\)31460-X](https://doi.org/10.1016/S0140-6736(16)31460-X) (2016).
3. Egede, L. E., Walker, R. J., Bishu, K. & Dismuke, C. E. Trends in Costs of Depression in Adults with Diabetes in the United States: Medical Expenditure Panel Survey, 2004–2011. *Journal of general internal medicine* **31**, 615–622, <https://doi.org/10.1007/s11606-016-3650-1> (2016).

4. Mushtaque, A., Gulati, R., Hossain, M. M. & Azmi, S. A. Prevalence of depression in patients of type 2 diabetes mellitus: A cross sectional study in a tertiary care centre. *Diabetes & metabolic syndrome* **10**, 238–241, <https://doi.org/10.1016/j.dsx.2016.06.016> (2016).
5. Rajput, R., Gehlawat, P., Gehlan, D., Gupta, R. & Rajput, M. Prevalence and predictors of depression and anxiety in patients of diabetes mellitus in a tertiary care center. *Indian journal of endocrinology and metabolism* **20**, 746–751, <https://doi.org/10.4103/2230-8210.192924> (2016).
6. Golden, S. H. *et al.* The Prevalence and Specificity of Depression Diagnosis in a Clinic-Based Population of Adults With Type 2 Diabetes Mellitus. *Psychosomatics* **58**, 28–37, <https://doi.org/10.1016/j.psych.2016.08.003> (2017).
7. Badescu, S. V. *et al.* The association between Diabetes mellitus and Depression. *Journal of medicine and life* **9**, 120–125 (2016).
8. Schmitt, A. *et al.* Depression is linked to hyperglycaemia via suboptimal diabetes self-management: A cross-sectional mediation analysis. *Journal of psychosomatic research* **94**, 17–23, <https://doi.org/10.1016/j.jpsychores.2016.12.015> (2017).
9. de Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E. & Lustman, P. J. Association of depression and diabetes complications: a meta-analysis. *Psychosomatic medicine* **63**, 619–630 (2001).
10. Takasaki, K., Babazono, T., Ishizawa, K., Miura, J. & Uchigata, Y. Relationship between diabetic nephropathy and depression: a cross-sectional analysis using the Diabetes Study from the Center of Tokyo Women's Medical University (DIACET). *BMJ open diabetes research & care* **4**, e000310, <https://doi.org/10.1136/bmjdr-2016-000310> (2016).
11. Novak, M. *et al.* Increased Risk of Incident Chronic Kidney Disease, Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression. *Diabetes care* **39**, 1940–1947, <https://doi.org/10.2337/dc16-0048> (2016).
12. Mut-Vitcu, G., Timar, B., Timar, R., Oancea, C. & Citu, I. C. Depression influences the quality of diabetes-related self-management activities in elderly patients with type 2 diabetes: a cross-sectional study. *Clinical interventions in aging* **11**, 471–479, <https://doi.org/10.2147/CIA.S104083> (2016).
13. Axon, R. N. *et al.* Comorbid depression is differentially associated with longitudinal medication nonadherence by race/ethnicity in patients with type 2 diabetes. *Medicine* **95**, e3983, <https://doi.org/10.1097/MD.0000000000003983> (2016).
14. Altinok, A., Marakoglu, K. & Kargin, N. C. Evaluation of quality of life and depression levels in individuals with Type 2 diabetes. *Journal of family medicine and primary care* **5**, 302–308, <https://doi.org/10.4103/2249-4863.192358> (2016).
15. Gonzalez, J. S. *et al.* Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. *Diabetes care* **30**, 2222–2227, <https://doi.org/10.2337/dc07-0158> (2007).
16. Derakhshanpour, F., Vakili, M. A., Farsinia, M. & Mirkarimi, K. Depression and Quality of Life in Patients With Type 2 Diabetes. *Iranian Red Crescent medical journal* **17**, e27676, [https://doi.org/10.5812/ircmj.17\(5\)2015.27676](https://doi.org/10.5812/ircmj.17(5)2015.27676) (2015).
17. Echeverry, D., Duran, P., Bonds, C., Lee, M. & Davidson, M. B. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial. *Diabetes care* **32**, 2156–2160, <https://doi.org/10.2337/dc09-0785> (2009).
18. Hermanns, N., Kulzer, B., Krichbaum, M., Kubiak, T. & Haak, T. How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment. *Diabetologia* **49**, 469–477, <https://doi.org/10.1007/s00125-005-0094-2> (2006).
19. Fisher, L., Gonzalez, J. S. & Polonsky, W. H. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabetic medicine: a journal of the British Diabetic Association* **31**, 764–772, <https://doi.org/10.1111/dme.12428> (2014).
20. Fisher, L. *et al.* Diabetes distress but not clinical depression or depressive symptoms is associated with glycemic control in both cross-sectional and longitudinal analyses. *Diabetes care* **33**, 23–28, <https://doi.org/10.2337/dc09-1238> (2010).
21. Fisher, L. *et al.* Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. *Diabetes care* **30**, 542–548, <https://doi.org/10.2337/dc06-1614> (2007).
22. Halliday, J. A. *et al.* Validation of the WHO-5 as a first-step screening instrument for depression in adults with diabetes: Results from Diabetes MILES - Australia. *Diabetes research and clinical practice* **132**, 27–35, <https://doi.org/10.1016/j.diabres.2017.07.005> (2017).
23. Fenwick, E. K. *et al.* What is the best measure for assessing diabetes distress? A comparison of the Problem Areas in Diabetes and Diabetes Distress Scale: results from Diabetes MILES-Australia. *Journal of health psychology*, 1359105316642006, <https://doi.org/10.1177/1359105316642006> (2016).
24. Egger, G., Donovan, R. J., Giles-Corti, B., Bull, F. & Swinburn, B. Developing national physical activity guidelines for Australians. *Australian and New Zealand journal of public health* **25**, 561–563 (2001).
25. Clarke, D. M., Marshall, R. J. & Smith, G. C. The construction of a brief case-finding instrument for depression in the physically ill. *Integr Psychiatry* **10**, 117–123 (1994).
26. Polonsky, W. H. *et al.* Assessing psychosocial distress in diabetes: development of the diabetes distress scale. *Diabetes care* **28**, 626–631 (2005).
27. Fisher, L., Hessler, D. M., Polonsky, W. H. & Mullan, J. When is diabetes distress clinically meaningful?: establishing cut points for the Diabetes Distress Scale. *Diabetes care* **35**, 259–264, <https://doi.org/10.2337/dc11-1572> (2012).
28. Li, C. *et al.* Prevalence and correlates of undiagnosed depression among U.S. adults with diabetes: the Behavioral Risk Factor Surveillance System, 2006. *Diabetes research and clinical practice* **83**, 268–279, <https://doi.org/10.1016/j.diabres.2008.11.006> (2009).
29. Barnacle, M., Strand, M. A., Werremeyer, A., Maack, B. & Petry, N. Depression Screening in Diabetes Care to Improve Outcomes: Are We Meeting the Challenge? *The Diabetes educator* **42**, 646–651, <https://doi.org/10.1177/0145721716662917> (2016).
30. Zhang, J. *et al.* Comparative study of the influence of diabetes distress and depression on treatment adherence in Chinese patients with type 2 diabetes: a cross-sectional survey in the People's Republic of China. *Neuropsychiatric disease and treatment* **9**, 1289–1294, <https://doi.org/10.2147/NDT.S49798> (2013).
31. Diabetes, A. Standards of medical care in diabetes—2013. *Diabetes care* **36**(Suppl 1), S11–66, <https://doi.org/10.2337/dc13-S011> (2013). American.
32. Jefford, M. *et al.* Rapid screening for depression—validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients. *British journal of cancer* **91**, 900–906, <https://doi.org/10.1038/sj.bjc.6602057> (2004).
33. Meader, N. *et al.* Case identification of depression in patients with chronic physical health problems: a diagnostic accuracy meta-analysis of 113 studies. *The British journal of general practice: the journal of the Royal College of General Practitioners* **61**, e808–820, <https://doi.org/10.3399/bjgp11X613151> (2011).
34. Knol, M. J. *et al.* Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. *Diabetologia* **49**, 837–845, <https://doi.org/10.1007/s00125-006-0159-x> (2006).
35. Nouwen, A. *et al.* Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. *Diabetologia* **53**, 2480–2486, <https://doi.org/10.1007/s00125-010-1874-x> (2010).
36. Gonzalez, J. S., Delahanty, L. M., Safren, S. A., Meigs, J. B. & Grant, R. W. Differentiating symptoms of depression from diabetes-specific distress: relationships with self-care in type 2 diabetes. *Diabetologia* **51**, 1822–1825, <https://doi.org/10.1007/s00125-008-1113-x> (2008).
37. Li, Z. *et al.* Diagnosed but Not Undiagnosed Diabetes Is Associated with Depression in Rural Areas. *International journal of environmental research and public health* **13**, <https://doi.org/10.3390/ijerph13111136> (2016).
38. Olvera, R. L., Fisher-Hoch, S. P., Williamson, D. E., Vatcheva, K. P. & McCormick, J. B. Depression in Mexican Americans with diagnosed and undiagnosed diabetes. *Psychological medicine* **46**, 637–646, <https://doi.org/10.1017/S0033291715002160> (2016).

39. Holt, R. I., de Groot, M. & Golden, S. H. Diabetes and depression. *Current diabetes reports* **14**, 491, <https://doi.org/10.1007/s11892-014-0491-3> (2014).
40. Papellbaum, M. *et al.* Depression, glycemic control and type 2 diabetes. *Diabetology & metabolic syndrome* **3**, 26, <https://doi.org/10.1186/1758-5996-3-26> (2011).
41. Lustman, P. J. *et al.* Depression and poor glycemic control: a meta-analytic review of the literature. *Diabetes care* **23**, 934–942 (2000).
42. Aikens, J. E., Perkins, D. W., Piette, J. D. & Lipton, B. Association between depression and concurrent Type 2 diabetes outcomes varies by diabetes regimen. *Diabetic medicine: a journal of the British Diabetic Association* **25**, 1324–1329, <https://doi.org/10.1111/j.1464-5491.2008.02590.x> (2008).
43. van der Feltz-Cornelis, C. M. *et al.* Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. *General hospital psychiatry* **32**, 380–395, <https://doi.org/10.1016/j.genhosppsych.2010.03.011> (2010).
44. Lustman, P. J., Freedland, K. E., Griffith, L. S. & Clouse, R. E. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. *Diabetes care* **23**, 618–623 (2000).
45. Chew, B. H. *et al.* The reliability and validity of the Malay version 17-item Diabetes Distress Scale. *Malaysian family physician: the official journal of the Academy of Family Physicians of Malaysia* **10**, 22–35 (2015).
46. Martinez-Vega, I. P., Doubova, S. V., Aguirre-Hernandez, R. & Infante-Castaneda, C. Adaptation and validation of the Distress Scale for Mexican patients with type 2 diabetes and hypertension: a cross-sectional survey. *BMJ open* **6**, e009723, <https://doi.org/10.1136/bmjopen-2015-009723> (2016).
47. Farm, B. A. S. *et al.* Translation, Revision, and Validation of the Diabetes Distress Scale for Indonesian Type 2 Diabetic Outpatients with Various Types of Complications. *Value in health regional issues* **12**, 63–73, <https://doi.org/10.1016/j.vhri.2017.03.010> (2017).
48. Gonzalez, J. S., Fisher, L. & Polonsky, W. H. Depression in diabetes: have we been missing something important? *Diabetes care* **34**, 236–239, <https://doi.org/10.2337/dc10-1970> (2011).
49. Joensen, L. E., Tapager, I. & Willaing, I. Diabetes distress in Type 1 diabetes—a new measurement fit for purpose. *Diabetic medicine: a journal of the British Diabetic Association* **30**, 1132–1139, <https://doi.org/10.1111/dme.12241> (2013).
50. Ting, R. Z. *et al.* Diabetes-related distress and physical and psychological health in chinese type 2 diabetic patients. *Diabetes care* **34**, 1094–1096, <https://doi.org/10.2337/dc10-1612> (2011).
51. Lin, E. H. *et al.* Relationship of depression and diabetes self-care, medication adherence, and preventive care. *Diabetes care* **27**, 2154–2160 (2004).
52. Peyrot, M. *et al.* Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. *Diabet Med* **22**, 1379–1385, <https://doi.org/10.1111/j.1464-5491.2005.01644.x> (2005).
53. Makine, C. *et al.* Symptoms of depression and diabetes-specific emotional distress are associated with a negative appraisal of insulin therapy in insulin-naïve patients with Type 2 diabetes mellitus. A study from the European Depression in Diabetes [EDID] Research Consortium. *Diabetic medicine: a journal of the British Diabetic Association* **26**, 28–33, <https://doi.org/10.1111/j.1464-5491.2008.02606.x> (2009).
54. Kahn, L. B., Marshall, J. A., Baxter, J., Shetterly, S. M. & Hamman, R. F. Accuracy of reported family history of diabetes mellitus. Results from San Luis Valley Diabetes Study. *Diabetes care* **13**, 796–798 (1990).

## Acknowledgements

We thank the participating patients and diabetes centres for their time and generous contribution to the Australian National Diabetes Audit activity. The Australian Commonwealth Department of Health and Ageing funds the Australian National Diabetes Audit activity. This research has received no specific grant from any other funding agency in the public, commercial or not-for profit sectors.

## Author Contributions

N.N.: study design, literature review, statistical analysis and interpretation, critical discussion, drafting and revision of the manuscript. A.P.: statistical analysis assistance, critical discussion, revision of the manuscript. SR: statistical analysis and interpretation of the data, revision of the manuscript, N.W.: study conception and design, revision of the manuscript, S.A.: study conception and design, revision of the manuscript, J.S.: critical discussion, critical revision of the manuscript. B.d.C.: study design, supervision of statistical analysis, critical discussion, critical revision of the manuscript. S.Z.: study conception and design, design of analyses, critical revision of the manuscript, supervision of the project. The authors N.N., S.R., and S.Z. had full access to the data and take responsibility for the integrity of the data and accuracy of the analysis. All authors have read and approved the final manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-018-26138-5>.

**Competing Interests:** W. Davis reports past participation in advisory boards and/or receiving honoraria from Novo Nordisk and Eli Lilly Australia. S. Andrikopoulos reports past participation in advisory boards and/or receiving honoraria from GlaxoSmithKline Pty Ltd, Novartis Pty Ltd, AstraZeneca Pty Ltd/Bristol-Myers Squibb Australia Pty Ltd, Eli Lilly Australia, Janssen Cilag Pty Ltd, Merck Sharp & Dohme (Australia) Pty Ltd, Sanofi Aventis Pty Ltd, Novo Nordisk, Servier Laboratories Pty Ltd. J Speight is a member of the Accu-Check Advisory Board (Roche Diabetes Care) and has attended Advisory Board meetings for Medtronic and Janssen. Her research group (The Australian Centre for Behavioural Research in Diabetes) has received honoraria in relation to the above Advisory Board meetings, unrestricted educational grants from Medtronic and Sanofi Diabetes; sponsorship to host or attend educational meetings from Lilly, Medtronic, MSD, Novo Nordisk, Roche Diabetes Care, and Sanofi Diabetes; consultancy income from Abbott Diabetes Care, Astra Zeneca, Roche Diabetes Care, and Sanofi Diabetes. S. Zoungas reports past participation in advisory boards/contract work on behalf of Monash University with AstraZeneca Pty Ltd, Merck Sharp & Dohme (Australia) Pty Ltd and Novo Nordisk Pty Ltd. S. Zoungas holds a NHMRC senior research fellowship. The remaining authors declare that they have no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018